NASDAQ:XXII - 22nd Century Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 173.28 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.47
▼ -0.04 (-1.59%)

This chart shows the closing price for XXII by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 22nd Century Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XXII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XXII

Analyst Price Target is $6.75
▲ +173.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for 22nd Century Group in the last 3 months. The average price target is $6.75, with a high forecast of $8.50 and a low forecast of $5.00. The average price target represents a 173.28% upside from the last price of $2.47.

This chart shows the closing price for XXII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in 22nd Century Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2022Dawson JamesBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.50N/A
7/23/2021CowenInitiated CoverageOutperform$5.00N/A
8/4/2020Bradley WoodsReiterated RatingBuyN/A
7/21/2019Chardan CapitalSet Price TargetBuy$12.00N/A
5/8/2019Chardan CapitalReiterated RatingBuy$11.50N/A
3/15/2019Chardan CapitalReiterated RatingBuy$11.50N/A
1/26/2018Chardan CapitalReiterated RatingBuy ➝ Buy$11.50N/A
10/16/2017Chardan CapitalBoost Price TargetBuy$3.50 ➝ $11.50N/A
3/7/2017Chardan CapitalReiterated RatingBuy$3.50N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/22/2021
  • 5 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/19/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2021
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
22nd Century Group logo
22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.
Read More

Today's Range

Now: $2.47
Low: $2.39
High: $2.52

50 Day Range

MA: N/A

52 Week Range

Now: $2.47
Low: $1.86
High: $6.07

Volume

1,654,047 shs

Average Volume

2,409,850 shs

Market Capitalization

$401.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of 22nd Century Group?

The following Wall Street analysts have issued stock ratings on 22nd Century Group in the last twelve months: Cowen Inc, Dawson James, and Zacks Investment Research.
View the latest analyst ratings for XXII.

What is the current price target for 22nd Century Group?

2 Wall Street analysts have set twelve-month price targets for 22nd Century Group in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 173.3%. Dawson James has the highest price target set, predicting XXII will reach $8.50 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $5.00 for 22nd Century Group in the next year.
View the latest price targets for XXII.

What is the current consensus analyst rating for 22nd Century Group?

22nd Century Group currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XXII will outperform the market and that investors should add to their positions of 22nd Century Group.
View the latest ratings for XXII.

What other companies compete with 22nd Century Group?

How do I contact 22nd Century Group's investor relations team?

22nd Century Group's physical mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company's listed phone number is (716) 270-1523 and its investor relations email address is [email protected] The official website for 22nd Century Group is www.xxiicentury.com.